Close menu

May 5th, 2022 | 11:52 CEST

Biotech-Investments also work conservatively: BioNTech, XPhyto, Valneva

  • Biotechnology
  • Pharma
  • Covid19
Photo credits:

Biotech stocks are often seen as all-or-nothing investments - either a bet works out, or the companies disappear into oblivion. But innovative companies in the pharmaceutical and biotech sectors do not always operate in just one area. They are not always spectacular projects that are dependent on approval procedures. We outline the investment opportunities around three well-known biotech stocks.

time to read: 3 minutes | Author: Nico Popp
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , VALNEVA SE EO -_15 | FR0004056851

Table of contents:

    BioNTech: Much ahead, much behind

    BioNTech's stock is clearly a Corona beneficiary. The manufacturer was the pioneer apart from Russia's Sputnik V vaccine and is still the top choice alongside Moderna when it comes to COVID-19 vaccines. But what else does BioNTech have to offer? Thanks to its flexible mRNA technology, the Mainz-based company has a wide range of options. At the end of last year, BioNTech announced a commitment to vaccines against influenza, tuberculosis, HIV and malaria. BioNTech is also repeatedly associated with the fight against cancer.

    After BioNTech's share price more than halved since the vaccine announcements in December, investors can focus on the share once again. The value seems to have stabilized above EUR 100. Since the pandemic does not seem to be over yet and new rounds of vaccination are becoming more and more likely, the wheels should continue to roll at BioNTech. The Company remains well-positioned and has a real cash cow in its portfolio with the covid vaccine.

    XPhyto: Hopeful biosensors

    The up-and-coming Canadian biotech company XPhyto has so far lacked a cash cow. However, the Canadians with good contacts in Germany are well-positioned in some niches. In particular, the biosensor business, which XPhyto uses to detect oral diseases such as periodontitis, peri-implantitis and stomatitis, in addition to covid infections, influenza and scarlet fever, could offer opportunities in the future. Just a few months ago, XPhyto acquired 3a-diagnostics GmbH, with which it had already cooperated, in its entirety. The goal at the time was to leverage synergies, create growth and commercialize the biosensors as quickly as possible. Five months after the takeover of 3a-diagnostics GmbH, investors can look forward to initial successes.

    In addition to the biosensor business, XPhyto also focuses on alternative dosage forms, such as patches or thin films that are placed under the tongue. With the help of innovative dosage forms, certain active ingredients can be used more effectively and thus at a lower cost. Especially around generics, where business is driven almost exclusively by price, cost advantages can quickly mean more market share. In addition to the two rather conservative pillars of biosensors and innovative dosage forms, XPhyto also offers research on psychedelic substances. This approach is socially acceptable, especially in North America, and is said to help treat depression, among other things. The XPhyto share has been languishing below the EUR 1 mark for months. If the rather down-to-earth business takes off, this could lead to a revaluation.

    Valneva: Hope thanks to Lyme disease vaccine

    The Valneva share shows that it can make sense to stand on several legs. Long hailed as a COVID-19 alternative, the Company recently suffered a setback in connection with the approval of the pandemic vaccine. By contrast, there was good news in connection with the planned Lyme disease vaccine. Especially now, in the summertime, the topic is coming back into focus. Lyme disease is transmitted by ticks and, along with meningococci, against which there is already a vaccine, is considered the more harmless consequence of tick bites. The disease can usually be treated well with antibiotics. The tricky thing is that Lyme disease symptoms vary and are often not recognized. So a vaccine would be beneficial and could effectively prevent complications around the nervous system, joints or even the heart that often accompany Lyme disease. Valneva's stock is currently at a crossroads. The value is still in an upward trend. Below EUR 10, however, the air is getting thin...

    Biotech companies do well to have several irons in the fire. While the development of drugs or vaccines is lengthy, expensive and risky, the bread-and-butter business around pharma and biotech also offers opportunities. XPhyto is well positioned around biosensors and alternative dosage forms and aims to be marketable in 2022. If it succeeds, the stock will stand in a new light.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.


    Commented by André Will-Laudien on September 28th, 2023 | 08:05 CEST

    Attention: Extended correction - Buy the right stocks now! Bayer, Viva Gold, TUI, and BASF are on the list!

    • Mining
    • Gold
    • Pharma
    • chemicals
    • travel

    Higher inflation and rising interest rates - this connection should be clear to investors. The interest rate level in Germany has moved from negative territory to 2.77% in the 10-year range, but stocks continued to rise cheerfully. The party led to all-time highs of 16,528 points in July, but the fundamental situation of the companies deteriorated in parallel. Only after repeated warnings from the US Federal Reserve did the explosive NASDAQ also enter a correction. And it continues. Yesterday, the CEO of US investment bank JPMorgan, Dimon, warned that the world may not be prepared for 7% capital market interest rates. He and Dr. Jens Erhardt, the CEO of the asset management company DJE, warn of stronger setbacks on the stock markets. Some stocks have already undergone a strong correction. Here is a brief overview.


    Commented by Nico Popp on September 27th, 2023 | 07:10 CEST

    Rich as a Sheikh? Here is what's happening: Schott Pharma, BioNTech, Cardiol Therapeutics

    • Biotechnology
    • Pharma

    High-tech or add-on? When Schott Pharma's shares go public in Frankfurt on Thursday, investors are likely to have a clear opinion. The manufacturer of pharmaceutical packaging may be attracting significant interest precisely because its business model is clearly defined. But what sets Schott apart, and which companies in the pharmaceutical and biotech industry might also become interesting? We provide insights and deliver answers!